We selected imatinib for our analysis as it shows promising but limited efficacy in clinical trials for NB and AML (NCT00030667 and NCT01126814) and is successfully used for chronic myeloid leukemia treatment, and both types of cancer express KIT, which is one of the main imatinib target. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.